2011-2015 Deep Research Report on Global and China PECVD Industry | Chemicals
November 25th, 2011 by Aarkstore Enterprise2011 HIV/AIDS Diagnostics Market: US, Europe, Japan–Sales Forecasts and Supplier Shares by Country | Pharmaceutical and Healthcare
November 24th, 2011 by Aarkstore Enterprise
News Media by Aarkstore.com announces, a new market research report is available in its vast collection.
The 2011 HIV/AIDS Diagnostics Market: US, Europe, Japan–Sales Forecasts and Supplier Shares by Country
http://www.aarkstore.com/reports/The-2011-HIV-AIDS-Diagnostics-Market-US-Europe-Japan-Sales-Forecasts-and-Supplier-Shares-by-Country-157131.html
The report presents a detailed analysis of the AIDS diagnostics market in the US, Europe, (France, Germany, Italy, Spain, UK) and Japan. Current scientific views on the definition, epidemiology and etiology of AIDS and other retroviruses are reviewed. The report provides the 5- and 10-year test volume and sales forecasts by country for HIV-1/2, HIV Ag, HTLV-I/II, Western Blot and other confirmatory tests performed in the following markets:
- Hospitals
- Public Health Labs
- Commercial/Private Labs
- Blood Banks
- Physician Offices
- Ambulatory Care CentersFor each country, in addition to the test volume and sales projections, the report presents the sales and market share estimates for major suppliers of AIDS tests.
Also, the report examines the market applications of DNA Probes, Monoclonal Antibodies, Immunoassays, IT and other technologies; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies emerging business expansion opportunities, alternative market penetration strategies, market entry barriers and risks, and strategic planning issues and concerns.
Browse All : Diagnostics Market Research Report
http://www.aarkstore.com/search/viewresults.asp?search=Diagnostics%20Market&PubId=&pagenum=1
Table of Contents :
I. Introduction
II. Worldwide Market and Technology Overview
A. Background
– Structure and Composition
– Classification
– Origin of AIDS
– Animal Lentivirus Systems
– Virus Receptos
– HIV Infections in Humans
- Pathogenesis & Pathology: Overview of HIV Infection Course
– CD4T Lymphocytes and Memory Cells
– Monocytes and Macrophages
– Lymphoid Organs
– Neural Cells
– Viral Coinfections
- Clinical Findings
– Plasma Viral Load
– Pediatric AIDS
- Neurologic Disease
- Opportunistic Infections
- Cancer
– Immunity
- Virus Isolation
- Serology
- Detection of Viral Nucleic Acid and Antigens
– Infectivity
– Epidemiology
- Worldwide Spread of AIDS
- United States
- Routes of Transmission
B. Diagnostic Tests
– Laboratory Diagnosis
- Enzyme Immunoassay Interpretation
- Specific, Sensitivity, and Predictive Value of Enzyme Immunoassays
– Competition Assays
– Western Blot Technique
– Immuno-Fluorescence Assay (IFA)
– Radioimmunoprecipitation
– HIV-1/HIV-2 Combination Testing
– Methods of HIV-Antigen Detection
– Antigen Assays and Blood Screening
– Urine Tests
– Immunopathogenic Mechanism of HIV Infection
– DNA Probes
- Overview
- Quantitative Polymerase Chain Reaction
- In Situ PCR
- Needed Improvements
– Viral Load/Drug Resistance Testing
– Genotype and Phenotype Testing
– Blood Banking Consideration
C. Vaccines and Drugs
- Antiviral Drugs
- Vaccines Against HIV
– Transmission of HIV in Blood Products
– HIV Transmission in Transplant and Artificial Insemination Recipients
D. Instrumentation Review and Market Needs
– Abbott AxSYM
– Abbott IMx/IMx Select
– Anagen AN2000/AuraFlex
– Beckman Coulter Access
– BioChem Pharma/SR1
– BioMerieux/Vitek Vidas
– Biotrol System 7000
– Chiron ACS: Centaur
– Chiron ACS: 180
– J&J Diagnostics/Amersham Amerlite
– J&J Diagnostics Vitros ECi
– Olympus PK310
– Roche Cobas Core
– Roche Elecsys 1010/2010
– Roche ES 22
– Roche ES 33
– Roche ES 300/300AL
– Siemens ELISA Processor II/III
– Siemens Immuno 1
– Siemens/Opus/Plus/Magnum
– Siemens Stratus
– Tosoh AIA-1200/1200DX/NexIA/600
– Wallac/Pharmacia Delfia
E. Emerging Diagnostic Technologies
1. DNA Probes
a. Technology Overview
b. Amplification Methods
– Polymerase Chain Reaction
- Robotics
- Temperature Cyclers
- PCR Variations
– Immuno-PCR
– QC-PCR
– DAP-PCR
– Ligase Chain Reaction
– Branched DNA
– Q-Beta Replicase
– Nucleic-Acid Sequence-Based
– Strand Displacement Activation
– Self-Sustained Sequence Replicase
Contact us at :
Aarkstore Enterprise
Abhishek Mankar
Tel: 09272852585
Email: enquiry@aarkstore.com
Website: www.aarkstore.com
Blog: http://www.emarketreports.com/
Aarkstore Enterprise-Mobile application developer survey: smartphone OS and runtime support
September 7th, 2010 by Aarkstore EnterpriseMobile application developer survey: smartphone OS and runtime support
The iPhone’s iOS is the clear favorite smartphone platform for mobile application developers, according to Ovum’s first mobile application developer survey. But while all five major smartphone platforms score well overall, it is BlackBerry OS and Windows Mobile that currently lead the opposition, rather than Android or Symbian. Overall, Java ME remains the leading mobile development environment, showing there’s still life – if not necessarily big profits - in an old and somewhat neglected technology. Meanwhile, full mobile web browsers are becoming a prime target for mobile developers, offering great promise of future application and content portability across devices and platforms.
This report is a companion to the previously published “Mobile application developer survey: network and channel requirements”, which focuses on non-device-related aspects of the survey.
Table of Contents :
Executive summary
In a nutshell
Ovum view
Key messages
Mobile developer platform choice
Five OSs attract most developer attention
iOS is the highest-priority mobile developer platform
Developers do accept some fragmentation
iPhone trend building traction for key rivals
BlackBerry and Android riding the iPhone success wave
Consumer appeal driving BlackBerry OS forward
Android has not yet fully shown its hand
Other platforms compete for remainder
Windows Phone developers keep the Microsoft faith
Symbian has lost its edge, if not yet its developers
Other OSs struggling for developer attention
Runtime and web platform preference
Older approaches still resonate – for now
Mobile web browser enters developer mainstream
Other cross-platform technologies also show potential
Developer support will again be limited to a subset
Factors influencing choice of development technology
Installed base and availability of devices provide greatest developer incentive
Appendix
Background to the study
Who did we survey?
List of Tables
Table 1: Aggregate device platform preference based on top-three rankings
List of Figures
Figure 1: Smartphone platforms that developers are currently supporting or plan to support
Figure 2: First-ranked smartphone platform among mobile application developers
Figure 3: Number of device platforms that developers are already supporting or are prepared to support
Figure 4: Second-ranked smartphone platform among mobile application developers
Figure 5: Cross-platform development environments that developers are already supporting or plan to support
Figure 6: First-ranked cross-platform development environments among mobile application developers
Figure 7: Device-side enablers and APIs most used by mobile application developers
Figure 8: Key factors influencing choice of developer technologies to support
Figure 9: First-ranked factor influencing choice of developer technologies to support
Figure 10: Second-ranked factor influencing choice of developer technologies to support
Figure 11: Size of companies interviewed (by employee numbers)
For more information please visit :
http://www.aarkstore.com/reports/Mobile-application-developer-survey-smartphone-OS-and-runtime-support-60522.html
Aarkstore Enterprise-Mobile application developer survey: smartphone OS and runtime support
September 7th, 2010 by Aarkstore EnterpriseMobile application developer survey: smartphone OS and runtime support
The iPhone’s iOS is the clear favorite smartphone platform for mobile application developers, according to Ovum’s first mobile application developer survey. But while all five major smartphone platforms score well overall, it is BlackBerry OS and Windows Mobile that currently lead the opposition, rather than Android or Symbian. Overall, Java ME remains the leading mobile development environment, showing there’s still life – if not necessarily big profits - in an old and somewhat neglected technology. Meanwhile, full mobile web browsers are becoming a prime target for mobile developers, offering great promise of future application and content portability across devices and platforms.
This report is a companion to the previously published “Mobile application developer survey: network and channel requirements”, which focuses on non-device-related aspects of the survey.
Table of Contents :
Executive summary
In a nutshell
Ovum view
Key messages
Mobile developer platform choice
Five OSs attract most developer attention
iOS is the highest-priority mobile developer platform
Developers do accept some fragmentation
iPhone trend building traction for key rivals
BlackBerry and Android riding the iPhone success wave
Consumer appeal driving BlackBerry OS forward
Android has not yet fully shown its hand
Other platforms compete for remainder
Windows Phone developers keep the Microsoft faith
Symbian has lost its edge, if not yet its developers
Other OSs struggling for developer attention
Runtime and web platform preference
Older approaches still resonate – for now
Mobile web browser enters developer mainstream
Other cross-platform technologies also show potential
Developer support will again be limited to a subset
Factors influencing choice of development technology
Installed base and availability of devices provide greatest developer incentive
Appendix
Background to the study
Who did we survey?
For more information please visit :
http://www.aarkstore.com/reports/Mobile-application-developer-survey-smartphone-OS-and-runtime-support-60522.html
Aarkstore–Who’s Doing What in Molecular Diagnostics? - The Results of the Kalorama Informatio
August 3rd, 2010 by Aarkstore EnterpriseWho’s Doing What in Molecular Diagnostics? - The Results of the Kalorama Information/Emmes Group Survey of U.S. Laboratories
From Kalorama Information a unique tool for assessing the diagnostic business today. Working in conjunction with premier diagnostic survey database Emmes Group, Kalorama Information presents the summarized results from a recent survey of a critical mass of diagnostic labs in the U.S, with analysis from Kalorama’s leading diagnostic analyst, Shara Rosen.
Far more than any other market research report, this report provides the most current and accurate picture of what is truly going on in molecular diagnostics in the United States.
Quantitative Data
Analyzed by the best-selling author of The Worldwide Market for In Vitro Diagnostics, now in its sixth edition, this new report includes surveys of molecular diagnostics focusing on these tests:
Chlamydia and Gonorrhea
HBV Viral Load
HCV Viral Load, HCV Genotyping
HIV Viral Load, HIV Genotyping
HPV, HPV Genotyping
Hospital Acquired Infections - MRSA, VRE
Coagulation Factors - Factor II, Factor V Leiden
Herpes Simplex Virus (HSV)
Oncology Tests - BCR/ABL, Bladder Cancer, Her2Neu, MTHFR
Transplant Medicine - HLA Typing
Hereditary Disorders - Cystic Fibrosis (CF), Fragile X
Respiratory Infections - Influenza A/B, Group A Strep, MTB (Tuberculosis), Bordetella pertussis, Adenovirus, Respiratory Virus
Communicable Diseases - CMV (Cytomegalovirus), EBV (Epstein-Barr Virus), Group B Strep, Enterovirus
What Labs Do Now, What They are Planning in the Future
There has been much analysis in recent years about the inroads that DNA testing has made. This unique resource offers a way to measure that progress, and test assumptions aobut the evolution of DNA testing, critical information to adjust business stratetgies. This report looks at the following topics:
What type of reagents are labs using (Commercial, ASR, Homebrew)
Where tests are performed (Central/Core Testing Lab, Chemistry Lab, Cytology Lab, Genetics Lab, Hematology Lab, Microbiology Lab, Molecular Lab, Pathology Lab, Serology/Immunology Lab, Virology Lab)
What Vendors are Labs Using
What are there Purchasing Plans
What Tests Do They Want in the Future
Do They Outsource and at what Rate?
Do They plan Vendor Changes?
A Representative Sample of the US Hospital Lab Industry
Emmes Group reached an extensive sample group - interviewing 14% of US hospital labs, 14% of public labs and 8% of US reference lab, where Emmes respondent numbers are compared to the Americian Hospital Directory. Such an undertaking would cost an individual company tens of thousands of dollars. This information is available to purchasers of this report at a fraction of the cost.
For more information please visit :
http://www.aarkstore.com/reports/Who-s-Doing-What-in-Molecular-Diagnostics-The-Results-of-the-Kalorama-Information-Emmes-Group-Survey-of-U-S-Laboratories-61338.html
Aarkstore Enterprise-World Market for Molecular Diagnostics , The Market Research Aggregator
August 3rd, 2010 by Aarkstore EnterpriseWorld Market for Molecular Diagnostics , The
Molecular diagnostics represents a revolution postponed, perhaps, but one that is now clearly underway. DNA Testing has emerged fully from research into clinical practice and becoming a dominant platform in clinical medicine.
From Emerging to Emergent Technology
Instrumentation now automates many of the sample preparation and assay steps that were formerly labor intensive. New tests are being launched all the time. At each step of the way, Kalorama Information has reported on its progress, and in this latest market research report we look at the present state of the market, and the advances that have made DNA testing routine. Many molecular tests are CE Marked and FDA-cleared and many more are in development. The result is that molecular testing is indicated in many areas of health care. Molecular Testing Compiled and Analyzed and Explained by a Leading Expert
Authored by lead Kalorama diagnostic analyst Shara Rosen, Kalorama Information’s World Market for Molecular Diagnostics is the most comprehensive global market report available on the emergent field of molecular diagnostics.
This report covers key platforms of molecular diagnostics, including the following :
Polymerase Chain Reaction (PCR)
Non-PCR Amplification Technologies, including:
bDNA
TMA
SDA
LIPA
NASBA
Invader
Others
In-situ Hybridization
Sequencing
Microarrays
Laser Capture Microdissection (LCM) and Tissue Arrays
Mass Spectroscopy
Other Molecular Platforms
For more information please visit :
http://www.aarkstore.com/reports/World-Market-for-Molecular-Diagnostics-The-12949.html
Aarkstore Enterprise-Clinical Nutrition Products: World Markets, 3rd Edition
August 3rd, 2010 by Aarkstore EnterpriseClinical Nutrition Products: World Markets, 3rd Edition
This Kalorama Information report - Clinical Nutrition - focuses on three primary segments of essential medical nutrition:
Infant Nutrition
Enteral Nutrition
Parenteral Nutrition
For each category, the report provides revenue data and forecasts for the most important segmentations. The report includes incidence of conditions which often require enteral or parenteral feeding, birth rates, over 65 population, and overall global population. Information is presented as a worldwide overview, with special emphasis on the U.S., Europe, and other key markets. The market segments provide an overview, description of products on the market, new developments, market estimates and forecasts, and competitive analysis of leading providers. The report also includes current issues and trends affecting the industry.
Coverage of Issues and Trends in Clinical Nutrition
There are several issues and trends that are impacting the clinical nutrition market, including:
Wound Care Applications
Reimbursement of Nutrition Products
Food Programs
Nutrition and Education
DHA and ANA Additives
Counterfeit Infant Formulas
Recalled Infant Formulas
Acquisition, Mergers and Alliances
Technology Applications
For more information please visit :
http://www.aarkstore.com/reports/Clinical-Nutrition-Products-World-Markets-3rd-Edition-12954.html
Aarkstore Enterprise–Vaccines 2009: World Market Analysis, Key Players, and Critical Trends
August 3rd, 2010 by Aarkstore EnterpriseVaccines 2009: World Market Analysis, Key Players, and Critical Trends in a Fast-Changing Industry
The global market for human vaccines has experienced strong growth through 2008 and this is expected to continue through the forecast period. Growth will be fueled by new product introductions and rising usage in all regions.
This report, Vaccines 2009: Key Players, and Critical Trends in a Fast-Changing Industry), examines the market for vaccines used in humans to previous various types of disease. Sales estimates for each market segment represent global revenues and are expressed in current dollars. Estimates are provided for the historic 2008 period and forecasts are provided through 2013.
Since the last edition of this report:
Vaccine makers are now advertising directly to the public with growing DTC budgets. The report identifies the possible market impact of this new trend.
The economy has impacted vaccine sales with more people unable to make required out of pocket payments for vaccination.
New categories of vaccines, such as allergy vaccines, are becoming more prominent, and have been included in our forecasts.
Several major new products, including Wyeth’s Prevnar 13, are on the horizon. The market impact of new products is discussed.
Two major mergers - Pfizer/Wyeth and Merck/Schering-Plough, will impact the industry and this is considered in our market analysis.
Few areas of pharmaceuticals have seen the fast-moving developments in the marketplace that the vaccine market has in 2008. Since last updated The World Market for Vaccines last year, new products and better than expected profits have transformed the vaccine marketplace. Continued sales of influenza vaccines and cervical cancer vaccines have provided a foundation for growth in the adult market. The competitive dynamics have changed with mergers, and many new products are on the way.
For more information please visit :
http://www.aarkstore.com/reports/Vaccines-2009-World-Market-Analysis-Key-Players-and-Critical-Trends-in-a-Fast-Changing-Industry-13838.html
Aarkstore Enterprise-DNA Sequencing Equipment and Services Markets, 2nd Edition
August 3rd, 2010 by Aarkstore EnterpriseDNA Sequencing Equipment and Services Markets, 2nd Edition
Since the last edition of DNA Sequencing Equipment and Services report, the market has been changing in unpredictable ways as second-generation sequencers are being incrementally introduced and upgraded. On the surface, the situation has become somewhat linear and predictable, but biotech analyst Justin Saeks explains, it is actually a unique and relatively volatile situation that is not seen often with life science tools markets. Third-generation systems have the potential to completely change the market, or to simply join the pack.
Revenue growth has been unusually high, and all of the trends seem to indicate that growth will continue in the near term. It is likely that completely new technologies will be introduced at least every year or two, while second-generation sequencer improvements also continue. In biotech analyst Justin Saek’s 2nd edition of DNA Sequencing Equipment and Services Markets, these changes are detailed and put in context, along with the following:
DNA Sequencer Revenues by Industry and by Leading Systems
Forecast of Sequencer Revenues to 2014
Review of Important Sequencers and Comparison of Features and Drawbacks.
Profiles of Major Companies in the Marketplace
Affymetrix and Illumina Settlement and other Significant Litigation in the Industry
Major Industry Deals since 2008, Review of Deals 05-07, and Analyst Commentary
Over 70 Figures and Tables making market information accessible
Review of Major Deals and Litigation affecting the marketplace.
Review of Technologies Under Development
Discussion of Funding Sources and Recent Grant Awardees
Strategic Recommendations for Companies Operating in the DNA Sequencing Market
DNA Sequencing Equipment and Service Markets represents research culled from a variety of secondary sources. But the true insights originated from interviews with market experts; these interviews were used to confirm numbers and test forecast assumptions.
Companies profiled in the report include:
454 Life Sciences / Roche
Applied Biosystems / Life Technologies
Beckman Coulter (Fullerton, CA)
GE Healthcare Life Sciences
Helicos Biosciences
Illumina / Solexa
LI-COR Biosciences (Lincoln, NE)
For more information please visit :
http://www.aarkstore.com/reports/DNA-Sequencing-Equipment-and-Services-Markets-2nd-Edition-23091.html
Aarkstore Enterprise-Point of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads
August 3rd, 2010 by Aarkstore EnterprisePoint of Care Diagnostics 2010 and Beyond: Rapid Testing at a Crossroads
As lead diagnostic analyst finds, the point of care concept is at a crossroads: the technologies needed to make rapid testing a reality are here. But is healthcare ready?
The drive for wellness and the attention surrounding healthcare reform will surely focus attention on rapid diagnostics. However, according to Shara Rosen, RT, M.B.A., there are many challenges which must be overcome for point of care solutions to fit, and those companies willing to pivot strategies and best adjust to changes in the healthcare marketplace may be rewarded.
This report, Point of Care Diagnostics 2010: Rapid Testing at a Crossroads represents the most current analysis of the role of Point of Care Diagnostics in today’s in vitro industry. Other reports have looked at products, companies and market forecasts, as this report does. But in her analysis Shara Rosen takes a bold look into the markets, technologies, and trends in decentralized testing with a special focus on the economics of rapid test use in critical care and emergency medicine. The report includes:
Markets for POC Diagnostics (Diabetes, Cardiac markers, Clinical Chemistry/Critical Care, Hematology, Coagulation,
Drugs of Abuse/Therapeutic Drug Monitoring, Infectious Diseases, Pharmacodiagnostics, Sepsis, Oncology, Women’s health / Pregnancy/Fertility)
By Venue Revenue Estimates for Hospital POC, Physician POC and Other Venue
Review of Products in the Market
Forecasts to 2013
Markets and Forecasts for Self-Testing (OTC)
The role of EMR in the Point of Care Market
Possible Effects of Healthcare Reform
POLs, Home Monitoring, Alternate Samples and Other Trends
Successful Strategies of POC Companies
Profiles of Over 100 Companies Competing in this Market
There are many factors in the growth of POC testing- increasing numbers of diagnosed diabetics, people with cardiovascular disease, and other chronic conditions. It is also expected to play a role in a trend in health care to evaluate provider organizations for quality in care delivery. While this quality imperative is most apparent in pay-for-performance systems, it also provides a framework by which public funds can be used more rationally. This is an especially relevant technology given the U.S. healthcare reform efforts.
All countries are feeling the brunt of aging populations and an increased burden of chronic disease management. Employers and insurance companies are interested in improving the health of customers, and there are some innovative tactics developing in this area. The report is conservative in its predictions and offers a calculated look into the future, based on events currently taking place.
The report offers a quantitative assessment of specific markets in US dollars for 2008 and forecasted out to 2013. These data are provided in order to set the status quo of tests and technologies. However the report concentrates on how these will impact the economics of healthcare over the near term and longer when possible.
For more information please visit :
http://www.aarkstore.com/reports/Point-of-Care-Diagnostics-2010-and-Beyond-Rapid-Testing-at-a-Crossroads-33983.html
Aarkstore Enterprise